Farringdon Capital, Ltd. Madrigal Pharmaceuticals, Inc. Transaction History
Farringdon Capital, Ltd.
- $242 Billion
- Q4 2024
A detailed history of Farringdon Capital, Ltd. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Farringdon Capital, Ltd. holds 697 shares of MDGL stock, worth $235,028. This represents 0.09% of its overall portfolio holdings.
Number of Shares
697Holding current value
$235,028% of portfolio
0.09%Shares
1 transactions
Others Institutions Holding MDGL
# of Institutions
338Shares Held
22.7MCall Options Held
757KPut Options Held
960K-
Janus Henderson Group PLC London, X02.21MShares$745 Million0.36% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$689 Million38.14% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$684 Million9.12% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$672 Million10.03% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$666 Million6.75% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.77B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...